OptiBiotix Health signs manufacturing and supply deal in India with Akums

OptiBiotix Health has entered into a five year agreement with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply products featuring OptiBiotix’s cholesterol and blood pressure reducing strain LPLDL in India.

IDMC recommends to expand Tiziana’s phase 2a trial of Milciclib

Tiziana Life Sciences announces that the independent data monitor committee (IDMC) completed a second, interim analysis of tolerability data from the first eleven treated patients and recommended expansion of the initial cohort to continue enrolment of an additional 20 patients to complete the trial.

FDA declines to approve Evolus’ DWP-450 for glabellar lines

The US Food and Drug Administration (FDA) has declined to approve Evolus’ application seeking approval of DWP-450 to treat glabellar lines in adult patients.

Surface Pharmaceuticals secures $20m funding from Flying L Partners

Surface Pharmaceuticals, an affiliated company of Imprimis Pharmaceuticals, has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise proceeds of about $20m in a private placement of its Series A preferred stock.

Novartis completes $8.7bn acquisition of AveXis

Novartis has completed its $8.7bn acquisition of US-based clinical stage gene therapy company AveXis via the consummation of a merger of its indirect wholly-owned subsidiary, Novartis AM Merger with and into AveXis.

FDA approves Pfizer’s epoetin alfa biosimilar Retacrit to treat anemia

Pfizer’s Retacrit (epoetin alfa-epbx), a biosimilar to Amgen’s anemia drug Epogen/Procrit (epoetin alfa), has been approved by the US Food and Drug Administration (FDA) for all indications of the reference product.

Zymeworks, Daiichi Sankyo expand immuno-oncology partnership

Zymeworks and Daiichi Sankyo have entered into a new license agreement, building upon their cross-licensing and collaboration agreement signed in 2016.

Aquestive settles Suboxone drug patent infringement case with Par Pharmaceuticals

Aquestive Therapeutics has reached a settlement agreement resolving patent litigation related to Suboxone (buprenorphine and naloxone) Sublingual Film with Par Pharmaceuticals.

Lilly to acquire AurKa Pharma in $575m deal

Eli Lilly and Company (Lilly) has agreed to acquire Canadian cancer drug developer AurKa Pharma from TVM Capital Life Science in a deal worth $575m.

AstraZeneca’s COPD drug Fasenra fails to meet primary endpoint in phase III trial

AstraZeneca’s respiratory drug Fasenra (benralizumab) has failed to meet its primary endpoint in the Galathea phase III trial.